FDA Places Partial Hold on Xencor’s Phase 1 Trial of XmAb14045 Immunotherapy for Blood Cancers
News
The U.S. Food and Drug Administration has placed a partial clinical hold on Xencor’s Phase 1 clinical trial of XmAb14045 for acute myeloid leukemia and other CD123-positive blood cancers because of ... Read more